TScan Therapeutics, Inc. (TCRX)

NASDAQ: TCRX · Real-Time Price · USD

1.080

+0.045 (4.35%)

At close: Mar 4, 2026, 4:00 PM EST

1.090

+0.010 (0.93%)

After-hours: Mar 4, 2026, 7:01 PM EST

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Development of TCR-T Therapies for Treatment of Patients with Cancer	2.82M	21.05M	13.54M	10.14M	1.09M
Development of TCR-T Therapies for Treatment of Patients with Cancer Growth	-86.62%	55.52%	33.47%	834.65%	-
Total	2.82M	21.05M	13.54M	10.14M	1.09M
Total Growth	-86.62%	55.52%	33.47%	834.65%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
United States	2.82M	21.05M	13.54M	10.14M	1.09M
United States Growth	-86.62%	55.52%	33.47%	834.65%	-
Total	2.82M	21.05M	13.54M	10.14M	1.09M
Total Growth	-86.62%	55.52%	33.47%	834.65%	-

Source: S&P Global Market Intelligence.